Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Oct 4, 2011

Premium

Michael Glynn has been appointed to chief commercial officer at Pacific Biosciences. He joins PacBio from Genzyme, where he served as the regional president of Japan and Asia Pacific, and also as a senior vice president.

Previously, he spent seven years at Boston Scientific, most recently as president of its Endovations division in the US. He also held various roles at Memtec, Baxter International, Burroughs Wellcome, Estee Lauder, and Elizabeth Arden.

He holds an MBA from Macquarie University in Sydney and a BS from the National University of Ireland.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.